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1. Introduction 
American Thoracic Society (ATS) and European Respiratory Society (ERS) define an 
exacerbation as an acute change in a patient’s baseline dyspnea, cough, or sputum that is 
beyond normal variability, and that is sufficient to warrant a change in therapy(Celli 
MacNee 2004). Exacerbations have a negative impact on mortality and morbidity and as 
the disease progress, the frequency and severity of exacerbations increase, leading to a fall 
in the quality of life of COPD patients. There is no standard method or tool for the 
diagnosis of an exacerbation. The changes in the clinical status of the patient should be 
taken into account. 
The most important parameters predicting mortality in patients who are hospitalized due 
to an acute exacerbation are; severity and stage of COPD, advanced age, co morbidities 
such as diabetes mellitus or cardiovascular disease, need of intubation and mechanical 
ventilation, high APACHE II score, presence of sepsis and multi organ failure 
(Groenewegen et al. 2003). 
2. Etiology of exacerbations 
Tracheobronchial infections (40-50% bacterial, 30-40% viral, 5-10% atypical bacteria) are 
involved in 50-70% of COPD exacerbations. Another factor is air pollution that is thought to 
be involved in 10% of exacerbations. In about 30%, the etiologic factor cannot be 
identified(Sapey Stockley 2006). Other medical problems, such as congestive heart failure, 
nonpulmonary infections, pulmonary embolism, and pneumothorax, can also lead to a 
COPD exacerbation. 
Infections: 
Bacterial: (Streptococcus pneumonia, Haemophilus influenza, Moraxella catarrhalis, 
Chlamydia pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus) 
Viral: (Rhinovirus, influenza, adenovirus, parainfluenza, coronavirus, respiratory cincitial 
virus) 
Environmental factors: 
Indoor and outdoor air pollution 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
292 
Patients who are known to have COPD are defined as an exacerbation when they are 
admitted to the emergency departments with increased dyspnea during fall and winter. The 
main issue is the underestimation of non-infectious causes such as pulmonary embolism, 
pleural effusion, pneumothorax, thoracic traumas, inappropriate use of sedatives, narcotics 
and beta blockers, arrhythmias, cardiac failure or problems in the use of long term oxygen 
therapy. Therefore, in a COPD patient with increased dyspnea, first the diagnosis of 
exacerbation should be established correctly and then the etiology should be identified as 
infectious or non-infectious. 
Potentially pathogen bacteria are identified in 30% of sputum cultures in mild 
exacerbations, while this rate can be up to 70% in severe exacerbations in patients who need 
ventilatory support (Sapey Stockley 2006; Siddiqi Sethi 2008). 
3. Initial evaluation of an exacerbation 
There are two main steps in the evaluation of a COPD exacerbation. The first step is the 
determination of severity of the disease that will guide the physician about the treatment 
approach and hospitalization decision. The second step is the identification of the etiologic 
cause and decide whether to initiate antibiotherapy or not. 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies COPD 
exacerbations as mild, moderate or severe, based on the intensity of the medical 
intervention required to control the patient’s symptoms (Table 1)(Rabe et al. 2007).  
 
Clinical history 
Mild 
(home treatment) 
Moderate 
(hospital treatment)
Severe 
(ICU treatment) 
Comorbidity + +++ +++ 
Frequent exacerbation 
history 
+ +++ +++ 
COPD stage Mild/Moderate Moderate/Severe Severe 
Hemodynamic status Stable Stable Stable/Unstable 
Accessory respiratory 
muscle use, cyanosis, 
paradoxal breathing, 
cyanosis, tachypnea 
No ++ +++ 
Change in neurologic status No No Yes 
Symptoms of right heart 
failure 
No ++ +++ 
Persistence of symptoms 
despite drug therapy 
No ++ +++ 
+: probably doesn’ t exist, ++: probably exists, +++: strongly may exist, ICU: intensive care unit 
Table 1. Classification of COPD exacerbations 
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Another classification approach is suggested by Anthonisen and colleagues (Anthonisen 
et al. 1987). According to this approach, severe exacerbations requiring antibiotheraphy 
are characterized by the presence of increase in all of the 3 criteria: dyspnea, sputum 
production and sputum purulence. Moderate exacerbations show only the 2 of these 
criteria, while in mild exacerbations, only one of these criteria is present with a recent 
history of upper airway infection or fever or symptoms like wheezing, cough, tachypnea 
and tachycardia. 
Diagnostic evaluation of a suspected COPD exacerbation varies whether the patient will 
be treated in the hospital or at home. Routine sputum culture evaluation is not 
recommended for mild exacerbations. In case of a severe exacerbation, oxygen saturation 
must be measured by a pulse oxymeter. Patients who are referred to a hospital must be 
evaluated by advanced diagnostic tests such as arterial blood gas analysis, chest x-ray, 
sputum gram staining and cultures, electrocardiography and blood drug levels if possible 
(Table 2). 
 
Diagnostic procedures Mild Moderate Severe 
Oxygen saturation Yes Yes Yes 
Arterial blood gas analysis No Yes Yes 
Chest X-ray No Yes Yes 
Blood tests * No Yes Yes 
Serum drug concentrations** If possible If possible If possible 
Sputum gram staining and cultures No Yes Yes 
ECG No Yes Yes 
BNP † No No Yes 
Cardiac enzyme measurement ‡ No No Yes 
*: blood cell count, serum electrolytes, urea, creatinine, liver function tests. 
**: theophylline, warfarin, carbamazepine, digoxin 
†: One third of dyspnea in chronic lung disease may be attributable to congestive heart failure. 
‡: Cardiac ischemia (myocardial infarction is underdiagnosed in patients with COPD). 
Table 2. Diagnostic evaluation of patients with suspected COPD exacerbation 
About 50% of COPD exacerbations are not reported to physicians(Seemungal et al. 2000). 
This suggests that half of the exacerbations are mild and do not require hospitalization. 
Indications for hospitalization of a patient with COPD exacerbation are as follows: 
1. Onset of new physical signs such as cyanosis, peripheral edema, detoriation in the 
neurological status, arrhythmias etc. 
2. Having severe or very severe COPD and being under long term oxygen therapy at 
home. 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
294 
3. No response to initial drug therapy. 
4. Pulmonary (pneumonia), or non-pulmonary (cardiac disease, diabetes mellitus) 
comorbidities with high risk. 
5. Having exacerbations often. 
6. Newly diagnosed arrhythmias. 
7. Diagnostic uncertainty. 
8. Advanced age. 
9. Detoriation in the arterial blood gas analysis results  
(pH< 7.35 or PaO2< 60mmHg or SaO2< 90%) 
10. Insufficient home support 
4. Treatment of COPD exacerbations 
All moderate and severe exacerbations must be evaluated in the hospital and in all severe 
exacerbations; arterial blood gas analysis must be performed. The patient must be 
evaluated immediately in terms of respiratory failure and oxygen therapy must be 
initiated if needed. Life threatening exacerbations should be followed up in the ICU. 
Respiratory failure with hypercapnia and respiratory acidosis is related with high 
mortality both at the time of admission and also during the 12 months follow up. While 
carbon dioxide retention is possible in moderate and severe exacerbations under oxygen 
therapy, arterial blood gas analysis must be performed every 30-60 minutes in order to 
detect the PaCO2 and pH levels.  
The inhaled oxygen concentration must be titrated to achieve a SaO2> 90% or a PaO2> 60 
mmHg. High-flow oxygen devices deliver oxygen more effectively than nasal canulas but 
nasal canulas may be tolerated better. If adequate oxygenation cannot be achieved by high 
flow masks or if the acidosis begins worsening (pH<7.35 and/or PaCO2> 50mmHg), 
noninvasive ventilation (NIV) is indicated. Success rates of NIV in COPD exacerbations are 
reported as 80-85% (Mehta&Hill 2001). The effect of NIV must be evaluated at the end of 
first and second hour by an arterial blood gas analysis. If there is worsening in the arterial 
blood gas result or if the patients cannot tolerate NIV, has worsening hypoxemia or has 
severe comorbidities such as myocardial infarction, hemodynamic instability, severe 
arrhythmias or sepsis, intubation and invasive mechanical ventilation must be initiated 
immediately.  
Short acting inhaled β-2 agonists are the first line preferred drugs for COPD exacerbations. 
The dosage and frequency of these drugs must be increased. Another option is to add an 
inhaler short acting anticholinergic drug or increase the dosage if the patient is already 
taking the drug. Nevertheless, the effectiveness of this combination still remains 
controversial. If there is a long acting bronchodilator the patient is not using, it can also be 
added to the therapy even though there is no clinical evidence showing the benefit of these 
drugs during an exacerbation. In severe exacerbations if the patient cannot inhale 
effectively, nebulised forms must be used. The role of theophylline in COPD exacerbations 
is controversial. If there is not enough response to short acting inhaled β-2 agonists, it can be 
used as a second choice drug. Serum levels must be obtained and patients must be followed 
carefully because of its cardiovascular side effects. 
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*Hospitalization in the last one month, frequent antibiotic use in the last one year, exacerbation causing 
severe respiratory failure, isolation of P. Aeruginosa  in the sputum culture during stable state or prior 
exacerbations. 
Table 3. Antibiotherapy options in infectious exacerbations of COPD 
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Adding systemic (oral or intravenous) glucocorticosteroids to other therapies in the hospital 
management of exacerbations of COPD is recommended (Niewoehner et al. 1999). Systemic 
use of corticosteroids may lead to fast recovery and improvement in hypoxemia and lung 
functions in COPD exacerbations. The recommended dosage of prednisolon is 30-40 
mg/day for 7-10 days if the patient has an initial FEV1 value below 50%. Prolonged 
treatment does not have a positive affect, besides it may increase the risk of side effects (e.g. 
muscle atrophy, hyperglycemia). 
Bronchoscopic studies showed that the amount of bacteria is increased nearly in 50% of 
COPD patients during an exacerbation when compared to the stable state(Sethi 2004). The 
decision to use antibiotics and the choice of antibiotic should be guided by the patient’s 
symptoms (e.g., presence of purulent sputum), recent antibiotic use, and local microbial 
resistance patterns. Prophylactic or continuous use of antibiotics does not improve outcome 
in patients with COPD (Rabe, Hurd et al. 2007). 
Even though the most common bacteria responsible for the exacerbations are H.influenzae, 
S. pneumoniae and M. Catarrhalis; some enteric Gram (-) bacteria and Pseudomonas 
aeruginosa are also isolated in most of the patiens with hypoxemia, severe airway 
obstruction, malnutrition, frequent hospitalization and antibiotic use history and 
comorbidity(Incalzi et al. 2006). There are some studies suggesting that atypical bacteria can 
also be an etiologic reason for an exacerbation but antibiotherapy targeting these bacteria 
showed no positive affect on clinical outcomes(Diederen et al. 2007; Tasbakan et al. 2007). 
Viruses can also be responsible in 15-40% of all exacerbations. Most of these are present with 
a bacterial infection. 
Antibiotherapy reduces the mortality rates and treatment failure especially in severe 
exacerbations of COPD(Puhan et al. 2007). Antibiotics also decrease the relapse rates of 
exacerbationsin outpatients(Adams et al. 2000). Therefore, antibiotherapy is strongly 
indicated expecially if the patient has purulant sputum and increase in dyspnea. Treatment 
options according to clinical status is summarized in Table 3. 
5. Preperation for hospital discharge 
In order to qualify for a discharge, the patient must have stable clinical conditions and a 
stable or improving arterial PaO2 of greater than 60mmHg. The patient should not require 
short acting β-agonist more often than every 4 hours. If the patient is stable and can use a 
metered dose inhaler, there is no extra benefit of using nebulised forms (Jenkins et al. 
1987). Patient education including topics such as medical treatment, nutrition, 
rehabilitation and physiotherapy programs and when to seek for professional medical 
help may improve the response to future exacerbations. Home support such as home 
mechanical ventilation, long term oxygen therapy, nebulisers or similar equipments 
should be arranged before discharge. 
6. Preventing future exacerbations 
Pulmonary rehabilitation, smoking cessation and immunization against influenza and 
pneumonia have been shown to improve health quality and reduce exacerbations in COPD 
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patients. There are also some data showing that long term oxygen therapy reduces the risk 
of hospitalization and shortens hospital stays in severely ill COPD patients. Long-acting 
inhaled bronchodilators and inhaled corticosteroids to improve symptoms and reduce the 
risk of exacerbations in patients with stable COPD are reviewed elsewhere with promising 
results. 
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